Immunome Analyst Price Targets - Benzinga

Immunome Inc

IMNMNASDAQ

Trade with Public

Trade with Public

$18.29

-0.47-2.51%

Últ. Act.: Oct 30, 4:11 AM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Informe de acciones

Immunome Analyst Price Targets

Wall Street analyst price targets and consensus rating for Immunome (IMNM).

Price Target Range — 13 Quarters

Analyst Consensus — 17 Analysts

16Buy

1Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$32Upside to Avg. PT+74.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 27, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$35
Oct 16, 2026	William Blair	Alethia Young	Initiate	Outperform	—
Oct 1, 2026	Stifel	Dara Azar	Initiate	Hold	$24
Sep 21, 2026	Alliance Global Partners	Matthew Venezia	Initiate	Buy	$32
Sep 10, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$40
Aug 12, 2026	Truist Securities	Supawat Thongthip	PT Raise	Buy	$37→$38
Aug 12, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$31→$35
Jul 21, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$31
Jun 12, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$31
May 28, 2026	Truist Securities	Supawat Thongthip	PT Raise	Buy	$36→$37
May 28, 2026	Barclays	Lukas Shumway	Initiate	Overweight	$36
May 15, 2026	Leerink Partners	Andrew Berens	PT Cut	Outperform	$37→$33
May 13, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$40
Mar 4, 2026	Craig-Hallum	Adam Vogel	PT Raise	Buy	$33→$36
Mar 4, 2026	Stephens & Co.	Sudan Loganathan	PT Cut	Overweight	$33→$30
Feb 12, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Initiate	Buy	$40
Jan 15, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$31
Dec 16, 2025	Lake Street	Chad Messer	PT Raise	Buy	$22→$32
Dec 16, 2025	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$18→$40
Dec 16, 2025	Guggenheim	Michael Schmidt	PT Raise	Buy	$25→$35

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Immunome, Maintains $35 Price Target

Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $35 price target.

Benzinga Newsdesk

PRO
William Blair Initiates Coverage On Immunome with Outperform Rating

William Blair analyst Alethia Young initiates coverage on Immunome (NASDAQ:IMNM) with a Outperform rating.

Benzinga Newsdesk

PRO
Stifel Initiates Coverage On Immunome with Hold Rating, Announces Price Target of $24

Stifel analyst Dara Azar initiates coverage on Immunome (NASDAQ:IMNM) with a Hold rating and announces Price Target of $24.

Benzinga Newsdesk

PRO
Alliance Global Partners Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $32

Alliance Global Partners analyst Matthew Venezia initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $32.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Immunome, Raises Price Target to $38

Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price target from $37 to $38.

Benzinga Newsdesk